Qinglv Wei

1.4k total citations · 1 hit paper
20 papers, 829 citations indexed

About

Qinglv Wei is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Qinglv Wei has authored 20 papers receiving a total of 829 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 10 papers in Cancer Research and 3 papers in Oncology. Recurrent topics in Qinglv Wei's work include RNA modifications and cancer (13 papers), Cancer-related molecular mechanisms research (9 papers) and RNA Research and Splicing (8 papers). Qinglv Wei is often cited by papers focused on RNA modifications and cancer (13 papers), Cancer-related molecular mechanisms research (9 papers) and RNA Research and Splicing (8 papers). Qinglv Wei collaborates with scholars based in China, United States and Belgium. Qinglv Wei's co-authors include Qingya Luo, Ping Yi, Yang Yu, Jianhua Yu, Li Li, Lanfang Li, Jia Yu, Chunming Cheng, Dongling Zou and Fang Wang and has published in prestigious journals such as Nucleic Acids Research, Nature Communications and Cancer Research.

In The Last Decade

Qinglv Wei

17 papers receiving 823 citations

Hit Papers

The m6A reader YTHDF1 promotes ovarian cancer progression... 2020 2026 2022 2024 2020 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Qinglv Wei China 10 774 424 91 67 53 20 829
Ruitu Lyu United States 11 776 1.0× 289 0.7× 76 0.8× 58 0.9× 5 0.1× 20 812
Ouwen Li China 6 232 0.3× 91 0.2× 64 0.7× 64 1.0× 9 0.2× 12 343
Panpan An China 8 493 0.6× 290 0.7× 29 0.3× 99 1.5× 2 0.0× 9 583
Liangliang Dong China 11 305 0.4× 216 0.5× 15 0.2× 35 0.5× 3 0.1× 25 420
Seth D. Kasowitz United States 5 483 0.6× 236 0.6× 71 0.8× 21 0.3× 5 0.1× 7 508
Valentina Miano Italy 10 477 0.6× 243 0.6× 19 0.2× 60 0.9× 2 0.0× 16 552
Wang Jia-hua China 3 1.0k 1.3× 532 1.3× 178 2.0× 65 1.0× 3 1.1k
Shilei Liu China 15 305 0.4× 134 0.3× 25 0.3× 118 1.8× 2 0.0× 39 498
Dominika Hroššová Czechia 8 697 0.9× 262 0.6× 57 0.6× 34 0.5× 8 721
Marc Bayer Germany 5 440 0.6× 162 0.4× 99 1.1× 31 0.5× 3 0.1× 7 473

Countries citing papers authored by Qinglv Wei

Since Specialization
Citations

This map shows the geographic impact of Qinglv Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qinglv Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qinglv Wei more than expected).

Fields of papers citing papers by Qinglv Wei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qinglv Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qinglv Wei. The network helps show where Qinglv Wei may publish in the future.

Co-authorship network of co-authors of Qinglv Wei

This figure shows the co-authorship network connecting the top 25 collaborators of Qinglv Wei. A scholar is included among the top collaborators of Qinglv Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qinglv Wei. Qinglv Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Wei, Qinglv, Jilei Xu, Xiaoyan Jiang, et al.. (2025). IGF2BP2 binding to CPSF6 facilitates m6A‐mediated alternative polyadenylation of PUM2 and promotes malignant progression in ovarian cancer. Clinical and Translational Medicine. 15(7). e70388–e70388. 1 indexed citations
3.
Wang, Yuya, Yifei Ren, Qinglv Wei, et al.. (2025). hnRNPL phase separation activates PIK3CB transcription and promotes glycolysis in ovarian cancer. Nature Communications. 16(1). 4828–4828.
5.
Jiang, Xiaoyan, et al.. (2024). Single-cell RNA sequencing and cell–cell communication analysis reveal tumor microenvironment associated with chemotherapy responsiveness in ovarian cancer. Clinical & Translational Oncology. 27(3). 1000–1012. 2 indexed citations
6.
Liu, Xiaoyi, Qinglv Wei, Hongyan Zhao, et al.. (2024). RNA m5C modification upregulates E2F1 expression in a manner dependent on YBX1 phase separation and promotes tumor progression in ovarian cancer. Experimental & Molecular Medicine. 56(3). 600–615. 27 indexed citations
7.
Wang, Haocheng, Qinglv Wei, Xiaoyi Liu, et al.. (2024). AKAP8 promotes ovarian cancer progression and antagonizes PARP inhibitor sensitivity through regulating hnRNPUL1 transcription. iScience. 27(5). 109744–109744. 1 indexed citations
8.
Wei, Qinglv, Xiaoyan Jiang, Yujiao Liu, et al.. (2024). CSTF3 contributes to platinum resistance in ovarian cancer through alternative polyadenylation of lncRNA NEAT1 and generating the short isoform NEAT1_1. Cell Death and Disease. 15(6). 432–432. 7 indexed citations
9.
Wei, Qinglv, et al.. (2023). NAT10-mediated RNA acetylation enhances HNRNPUL1 mRNA stability to contribute cervical cancer progression. International Journal of Medical Sciences. 20(8). 1079–1090. 21 indexed citations
10.
Chen, Yanjie, Qinglv Wei, Jie Xu, et al.. (2023). Upregulation of LRRC8A by m5C modification-mediated mRNA stability suppresses apoptosis and facilitates tumorigenesis in cervical cancer. International Journal of Biological Sciences. 19(2). 691–704. 41 indexed citations
11.
Wang, Haocheng, Qingya Luo, Qinglv Wei, et al.. (2021). YTHDF1 Aggravates the Progression of Cervical Cancer Through m6A-Mediated Up-Regulation of RANBP2. Frontiers in Oncology. 11. 650383–650383. 51 indexed citations
12.
Liu, Tao, Yang Yu, Qingya Luo, et al.. (2021). The RNA binding protein QKI5 suppresses ovarian cancer via downregulating transcriptional coactivator TAZ. Molecular Therapy — Nucleic Acids. 26. 388–400. 3 indexed citations
13.
Wei, Qinglv, Dan Yang, Xiaoyi Liu, et al.. (2021). Exploration of the Role of m6 A RNA Methylation Regulators in Malignant Progression and Clinical Prognosis of Ovarian Cancer. Frontiers in Genetics. 12. 650554–650554. 8 indexed citations
14.
Zhao, Zhonghua, et al.. (2021). Establishment of A New HBV Cell Culture Model by Covalently Closed Circular DNA Direct Transfect. IOP Conference Series Earth and Environmental Science. 632(3). 32023–32023.
15.
Liu, Tao, Qinglv Wei, Jing Jin, et al.. (2020). The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Research. 48(7). 3816–3831. 530 indexed citations breakdown →
16.
Yu, Yang, Qinglv Wei, Yuling Tang, et al.. (2020). Loss of hnRNPA2B1 inhibits malignant capability and promotes apoptosis via down-regulating Lin28B expression in ovarian cancer. Cancer Letters. 475. 43–52. 54 indexed citations
18.
Cao, Min, Zhonghua Zhao, Yuwei Tang, et al.. (2018). A new hepatitis B virus e antigen-negative strain gene used as a reference sequence in an animal model. Biochemical and Biophysical Research Communications. 496(2). 502–507. 4 indexed citations
19.
Wei, Qinglv, et al.. (2017). The Ste12-like transcription factor MaSte12 is involved in pathogenicity by regulating the appressorium formation in the entomopathogenic fungus, Metarhizium acridum. Applied Microbiology and Biotechnology. 101(23-24). 8571–8584. 30 indexed citations
20.
Wei, Qinglv, et al.. (2014). MaSnf1, a sucrose non-fermenting protein kinase gene, is involved in carbon source utilization, stress tolerance, and virulence in Metarhizium acridum. Applied Microbiology and Biotechnology. 98(24). 10153–10164. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026